A different TRAP220 expression in distinct histologic subtypes of lung adenocarcinoma and the prognostic significance

Yun, Jeanho; Son, Chang-Woo; Um, Soo-Jung; Kwon, Hyuk Chan; Lee, Jun Young; Choi, Phil Jo; Roh, Mee Sook

doi:10.1016/j.lungcan.2010.06.012

Cited by 14 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exact temporal and spatial regulation of the transcription of genes is vital to the execution of complex gene functions in response to growth, apoptosis, developmental and homeostatic signals, etc [15,16]. MED1 has been found to play an important coregulatory role in the development and progression of lung adenocarcinoma [17]. Although Mediator complex has been studied for many years, limited knowledge was known about MED19/LCMR1.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC

Chen

Liang

Tian

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundLung cancer is one of the most common human cancers and the leading cause of cancer death worldwide. The identification of lung cancer associated genes is essential for lung cancer diagnosis and treatment.MethodsDifferential Display-PCR technique was used to achieve the novel cDNA, which were then verified by real-time PCR. Northern blot was utilized to observe the expression of LCMR1 in different human tissues. 84 cases human NSCLC tissues and normal counterparts were analyzed for the expression of LCMR1 by immunohistochemistry.ResultsA novel 778-bp cDNA fragment from human large cell lung carcinoma cell lines 95C and 95D was obtained, and named LCMR1 (Lung Cancer Metastasis Related protein 1). LCMR1 was differentially expressed in different human tissues. LCMR1 was strongly overexpressed in NSCLC and its expression was significantly associated with clinical stage.ConclusionOur data indicated that LCMR1, strongly overexpressed in NSCLC, might have applications in the clinical diagnosis and treatment of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC

Chen

Liang

Tian

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Pulmonary adenocarcinoma is histologically heterogeneous and currently, there have been several reports of different molecular or immunohistochemical expressions of distinct histologic subtypes in lung adenocarcinoma 19,20. To the best of our knowledge, this is the first study to investigate the relationship between NKD1 expression and clinicopathological features, with special attention to the histologic pattern in small lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 91%

Naked Cuticle Drosophila 1 Expression in Histologic Subtypes of Small Adenocarcinoma of the Lung

et al. 2013

View full text Add to dashboard Cite

BackgroundNaked cuticle Drosophila 1 (NKD1) has been related to non-small cell lung cancer in that decreased NKD1 levels have been associated with both poor prognosis and increased invasive quality.MethodsForty cases of lung adenocarcinoma staged as Tis or T1a were selected. Cases were subclassified into adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and small adenocarcinoma (SAD). Immunohistochemical studies for NKD1 were performed.ResultsForty samples comprised five cases of AIS (12.5%), eight of MIA (20.0%), and 27 of SAD (67.5%). AIS and MIA showed no lymph node metastasis and 100% disease-free survival, whereas among 27 patients with SAD, 2 (7.4%) had lymph node metastasis, and 3 (11.1%) died from the disease. Among the 40 cases, NKD1-reduced expression was detected in 8 (20%) samples, whereas normal expression was found in 15 (37.5%) and overexpression in 17 (42.5%). Loss of NKD1 expression was significantly associated with lymph node metastasis (p=0.001). All cases with predominant papillary pattern showed overexpression of NKD1 (p=0.026).ConclusionsAmong MIA and SAD, MIA had better outcomes than SAD. Down-regulated NKD1 expression was closely associated with nodal metastasis, and overexpression was associated with papillary predominant adenocarcinoma.

show abstract

“…In BCa, high levels of urokinase have been linked to enhanced motility of BCa cell lines and metastatic spread (23). Further, in lung adenocarcinoma, decreased MED1 expression was associated with diverse parameters of malignancy such as advanced pT stage, positive lymphonodal status, and shorter survival (11). Overall, downregulation of MED1 has been linked to enhanced invasion and tumorigenic phenotype in several cancer entities, which may support our observed association of MED1 with clinicopathological parameters of worse outcome in BCa (10–12) (Figure 2).…”

Section: Discussionmentioning

confidence: 99%

“…There is great evidence for the kinase module CDK8 to function as an oncogene in colorectal carcinoma and its paralog CDK19 to be overexpressed during prostate cancer progression (8, 9). In melanoma, downregulation of the tail module MED1, also known as TRAP220, triggers a strong tumorigenic phenotype (10) and is associated with worse outcome in lung adenocarcinoma (11). Interestingly, loss of MED1 promotes the appearance of metastases of non-small-cell lung cancer cells by modulating metastasis-related genes (12) and was associated with the downregulation of tumor suppressor gene dapk1 (13).…”

Section: Introductionmentioning

confidence: 99%

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression

Klümper¹,

Syring

Vogel³

et al. 2017

Front. Med.

View full text Add to dashboard Cite

IntroductionBladder cancer (BCa) is among the most frequent cancer entities and relevantly contributes to cancer-associated deaths worldwide. The multi-protein Mediator complex is a central regulator of the transcriptional machinery of protein-coding genes and has been described to be altered in several malignancies. MED1, a subunit of the tail module, was described to negatively modulate expression of metastasis-related genes and to be downregulated in melanoma and lung cancer. In contrast, MED1 hyperactivity was described in breast and prostate cancer, likely due its function as a hub for nuclear hormone receptors. So far, only little is known about the function of the Mediator complex in BCa. The aim of this study was therefore to investigate the role of MED1 in BCa as a prognostic biomarker and a biomarker of disease progression.MethodsThe protein expression of MED1 was assessed by immunohistochemistry (IHC) on tissue microarrays from 224 patients: benign urothelium n = 31, non-muscle invasive BCa (pTis, pT1) n = 72, and muscle invasive BCa (pT2–T4) n = 121. Comprehensive clinicopathological information including follow-up were available. Quantification of MED1 protein expression was evaluated by the semiquantitative image analysis program Definiens.ResultsMED1 expression significantly decreased during BCa progression from benign urothelium to advanced BCa. Muscle invasion, the crucial step in BCa progression, was associated with low MED1 protein expression. Accordingly, decreased MED1 expression was found in primary BCa samples with positive lymphonodal status and distant metastases. Furthermore, cancer-specific survival was significantly worse in the group of low MED1 expression.ConclusionOur findings show that the downregulation of MED1 is associated with muscle invasion, metastatic spread, and shorter overall survival in BCa.

show abstract

A different TRAP220 expression in distinct histologic subtypes of lung adenocarcinoma and the prognostic significance

Cited by 14 publications

References 24 publications

Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC

Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC

Naked Cuticle Drosophila 1 Expression in Histologic Subtypes of Small Adenocarcinoma of the Lung

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression

Contact Info

Product

Resources

About